Biotech

  • Conference
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Top pharma industry conferences in 2027

    Where pharma and biotech leaders will converge to network, share ideas and potentially strike deals.

    By • Oct. 6, 2026
  • Pop-art illustration showing an injectable weight-loss medication, a bathroom scale and a person’s midsection.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    The next frontier in obesity drugs: lasting weight loss

    Alveus, Lilly, Viking and Amgen are testing maintenance strategies as durability becomes a bigger focus in obesity R&D.

    By Kelly Bilodeau • Oct. 6, 2026
  • digital pill Explore the Trendline➔
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Trendline

    Artificial intelligence & machine learning

    After years of excited buzz around the potential of artificial intelligence and machine learning, pharma has begun to realize the true implications and potential value of these technologies.

    By PharmaVoice staff
  • The exterior of the building housing the headquarters of Roche France, French subsidiary of the Swiss pharmaceutical group.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Roche’s AI lab; Biohaven’s pivotal pause

    Roche announced it's building autonomous AI-powered labs; how a clinical hold on an epilepsy trial could impact Biohaven

    By PharmaVoice Staff • Oct. 2, 2026
  • psychedelic clinical trials
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Are psychedelics as effective as trials suggest?

    Patients often know when they’ve received a psychedelic, potentially distorting trial results. Researchers are testing new ways to make those studies more reliable.

    By Kelly Bilodeau • Oct. 1, 2026
  • dna helix
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Beam sues 2 biotechs, alleging theft of base editing trade secrets

    Beam claimed a former scientist stole confidential information and quietly spun up a rival rare disease treatment at YolTech Therapeutics. Serapha Bio, which licensed that therapy, denies the charges. 

    By Gwendolyn Wu • Sept. 30, 2026
  • 3D-rendered network of glowing neurons firing against a dark background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Epilepsy R&D is breaking out of its old playbook

    Genetic medicines and more selective small molecules are finally pushing the field toward new mechanisms — and potentially disease-modifying treatments.

    By Kelly Bilodeau • Sept. 29, 2026
  • Digital illustration of a capsule containing a DNA helix and electronic circuitry against a purple and blue digital network.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Nimbus used AI to help develop Takeda’s $4B psoriasis bet. Here’s where it’s taking the tech next

    Nimbus Therapeutics’ head of R&D dishes on what’s next in AI-enabled drug discovery, years after Takeda completed its zasocitinib acquisition.

    By Alexandra Pecci • Sept. 25, 2026
  • Wall Street buildings
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Basecamp raises $140M before the clinic; J&J and Compass’ potential rivalry

    Some of the biggest news and trends captured in PharmaVoice’s newsletter this week. Sign up here to receive the newsletter daily. Another big AI haul Investors are still lining up to back AI drug developers before their candidates reach human trials. Basecamp Research...

    By PharmaVoice Staff • Sept. 25, 2026
  • vaccine vial
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    A norovirus breakthrough?; another women’s healthtech haul

    Yale researchers untangled norovirus RNA and Evvy just pulled in $40 million for precision medicine in women's health.

    By PharmaVoice Staff • Sept. 18, 2026
  • dark horse
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    A dark horse in the orexin race?

    As the orexin competition heats up in the neuroscience space, Harmony Biosciences is developing an early-stage asset it believes could have an edge over rivals.

    By • Sept. 18, 2026
  • eye
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Sling banks $123M for an experimental thyroid eye disease pill

    A confirmatory late-stage study is now also underway for what the startup is positioning as, potentially, the first oral alternative to approved injectables like Amgen's Tepezza and Viridian's Lumvoa.

    By Gwendolyn Wu • Sept. 17, 2026
  • Nasdaq logo and signage on the curved exterior of its MarketSite building, viewed from street level.
    Image attribution tooltip
    Michael M. Santiago via Getty Images
    Image attribution tooltip

    8 biotech IPO prospects testing investor appetite

    Fresh filings and older proposals reveal different tests of clinical evidence, financing needs and readiness for public ownership.

    By Sy Mukherjee • Sept. 17, 2026
  • Illustration of cancer cells with textured surfaces against a dark blue background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    3 KRAS drugs to watch as the field expands

    Revolution’s pancreatic cancer approval marked a milestone in RAS-targeted treatment. Now, new treatments from Revolution, Astellas and Genentech could be the next to make a mark on the space.

    By Kelly Bilodeau • Sept. 15, 2026
  • A laboratory microscope sits beside test tubes as a researcher works in the background.
    Image attribution tooltip
    howtogoto via Getty Images
    Image attribution tooltip

    Cancer still dominates pharma R&D. Obesity is gaining ground.

    Oncology still accounts for nearly two out of five pipeline drugs, while obesity entered the top 10 indications and one-third of drugs target at least one rare disease.

    By Alexandra Pecci • Sept. 11, 2026
  • An all-green glass building facade with a logo that reads "MERCK" is displayed on the exterior of the research facility.
    Image attribution tooltip
    Alamy
    Image attribution tooltip

    Merck builds around Keytruda; prediction markets raise new risks

    Merck pursues new cancer combinations, prediction markets put pharma’s confidential information in focus and personalized cancer vaccines confront manufacturing hurdles.

    By PharmaVoice Staff • Sept. 11, 2026
  • Gloved workers supervise rows of glass bottles on a pharmaceutical production line.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    mRNA cancer vaccines’ biggest barriers to market

    Manufacturing hurdles are just one challenge the industry must overcome to commercialize personalized mRNA cancer vaccines.

    By Alexandra Pecci • Sept. 10, 2026
  • A gloved scientist holds a blood sample in front of a monitor displaying a brain MRI scan.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    5 questions that could determine Alzheimer’s next chapter

    “The Alzheimer’s space has really got a fire under it,” says one analyst. But can the momentum deliver better drugs?

    By Kelly Bilodeau • Sept. 9, 2026
  • A sign for the Food And Drug Administration is seen outside of the headquarters on July 20, 2020 in White Oak, Maryland.
    Image attribution tooltip
    Sarah Silbiger via Getty Images
    Image attribution tooltip

    FDA gains ‘continuity’ as Mikhail, Davis named permanent CBER, CDER leaders

    After almost two years of turnover in the FDA’s top ranks, the new appointments should help ease concerns about more turmoil ahead, one analyst said. 

    By Kristin Jensen • Sept. 9, 2026
  • Gilead sign
    Image attribution tooltip
    Justin Sullivan via Getty Images
    Image attribution tooltip

    Gilead’s growing HIV franchise; cell therapy licensing deals plummet

    The FDA recently OK'd Gilead's novel HIV combo med, and cell therapy deals have fallen dramatically in two years.

    By PharmaVoice Staff • Sept. 4, 2026
  • Measles
    Image attribution tooltip
    Joe Raedle via Getty Images
    Image attribution tooltip

    As measles outbreaks soar, where does drug R&D stand?

    More than 25 years after it was declared eliminated, measles has surged back. But drug R&D is still in early stages and up against a tense market environment.

    By Alexandra Pecci • Sept. 4, 2026
  • A technician in protective clothing stands beside manufacturing equipment in a pharmaceutical laboratory.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    The hidden scale-out problem behind CAR-T’s growth

    CAR-T’s commercial challenge isn’t making bigger batches. It’s making thousands of patient-specific manufacturing runs behave like one reliable system. In vivo aims to eliminate the batch altogether.

    By Sy Mukherjee • Sept. 1, 2026
  • A woman stands against a wall while blurred people walk past her in the foreground.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Social anxiety drugs have been floundering in the clinic. Could Eli Lilly help tip the scales?

    After two notable failures, the social anxiety R&D space gained a major player when Eli Lilly agreed to acquire AtaiBeckley this year.

    By Alexandra Pecci • Aug. 31, 2026
  • Karen Massey headshot
    Image attribution tooltip
    Permission granted by Argenx
    Image attribution tooltip
    Q&A // First 90 Days

    A single drug made Argenx one of the most valuable biotechs in Europe. Its new CEO is ready for the next act.

    Under its new chief, Karen Massey, Argenx is positioning its blockbuster Vyvgart to become the Keytruda of the autoimmune disease space.

    By • Aug. 28, 2026
  • Syringes embedded in a dartboard around the bullseye.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    3 takeover targets in immunology

    Dealmaking in the autoimmune space is thriving as biotechs chase new targets with the potential to treat more conditions.

    By Kelly Bilodeau • Aug. 26, 2026
  • futurey lab
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Q&A

    Is AI finally proving its worth in drug R&D?

    A Tufts analysis found that an AI clinical monitoring agent could deliver up to $21 million in value for a late-stage program in oncology R&D. But will the findings apply in more therapeutic areas?

    By Kelly Bilodeau • Aug. 26, 2026